Browse > Article
http://dx.doi.org/10.15324/kjcls.2018.50.2.197

Expression of MicroRNA-221 in Korean Patients with Multiple Myeloma  

Choi, Woo-Soon (Department of Clinical Laboratory Science, Songho University)
Publication Information
Korean Journal of Clinical Laboratory Science / v.50, no.2, 2018 , pp. 197-204 More about this Journal
Abstract
Multiple myeloma (MM) is the leading cause of death among hematologic neoplasms. Recently, microRNA has been reported to be useful in the diagnosis of multiple myeloma. This study examined whether miR-221 could be used as a diagnostic marker for multiple myeloma. The study was performed on 20 patients with multiple myeloma without any other hematological diseases. MicroRNA extraction was performed using formalin-fixed paraffin-embedded (FFPE) tissues obtained from the bone marrow of patients with multiple myeloma. miR-15a, miR-16, miR-21, miR-181a, and miR-221 were selected as the microRNA target genes for multiple myeloma. The significance of microRNA was based on a fold change of <1.5. To quantify the fold changes, data normalized to the human gene, SNORD43, were used as the values of the patient group. Fold change values greater than 1.5 were defined as "overexpression", whereas values less than -1.5 were defined as "underexpression". Of note, 65.0% (13/20) of samples showed significant "overexpression" in the levels of miR-221 expression and plasma cells with a group of more and less than 30% in MM patients did not show any significance of plasma cell (P<0.05). The results of other studies showing a correlation between the expression of miR-221 and MM in Caucasians were confirmed. These results suggest that miR-221 may be a useful indicator for diagnosing patients with MM. In conclusion, miR-221 is useful in the diagnosis and determining the prognosis of multiple myeloma in Koreans.
Keywords
Bone marrow; Hematologic neoplasms; MicroRNAs; Multiple myeloma; Plasma cells;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Loffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermuller J, Kretzschmar AK, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediatde induction of microRNA-21 through a highly conserved enhancer. Blood. 2007;110:1330-1333. doi:10.1182/blood-2007-03-081133.   DOI
2 Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken MM, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer. 2007;120(Suppl 12):40-61. doi:10.1002/ijc.22718.   DOI
3 Ribatti D, Nico B, Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene. 2006;25:4257-4266. doi:10.1038/sj.onc.1209456.   DOI
4 Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420. doi:10.1200/JCO.2005.04.242.   DOI
5 Chng WJ1, Lau LG, Yusof N, Mow BM. Targeted therapy in multiple myeloma. Cancer Control. 2005;12:91-104. doi:https://doi.org/10.1016/ S0037-1963(01)90021-6.
6 Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374:324-339. doi: 10.1016/S0140-6736(09)60221-X.   DOI
7 Kumar S. Multiple myeloma-current issues and controversies. Cancer Treat Rev. 2010;36(Suppl 2):3-11. doi:10.1016/S0305-7372(10)70006-2.   DOI
8 Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704-714. doi: 10.1038/nrg2634.   DOI
9 Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF. et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569. doi:10.1146/annurev.arplant.57.032905.105218.   DOI
10 Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009;113:6669-6680. doi:10.1182/blood-2009-01-198408.   DOI
11 Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J. The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol. 2009;84:1-16. doi:10.1111/j.1600-0609.2009.01348.x.
12 Corthals SL, Jongen-Lavrencic M, de Knegt Y, Peeters JK, Beverloo HB, Lokhorst HM, et al. Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leuk Res. 2010;34:677-681. doi:10.1016/j.leukres.2009.10.026.   DOI
13 Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299:425-436. doi:10.1001/jama.299.4.425.
14 Kim YK, Yu J, Han TS, Park SY, Namkoong B, Kim DH, et al. Functional links between clustered microRNAs: suppression of cell cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res. 2009;37:1672-1681. doi:10.1093/nar/gkp002.   DOI
15 Chang HJ, Kim NK, Jeon YJ, Kim JW. The relationship between the progression of colorectal cancer and microRNA polymorphisms. Korean J Clin Oncol. 2011;7:50-57. doi: 10.14216/kjco.11019.   DOI
16 Son JW, Kim YJ, Cho HM, Lee SY, Jang JS, Choi JE, et al. MicroRNA expression profiles Korean non-small cell lung cancer. Tuberc Respir Dis. 2009;67:413-421. doi:https://doi.org/10.4046/trd.2009.67.5.413.   DOI
17 Lee HJ, Park CS, Deftereos G, Morihara J, Stern JE, Hawes SE, et al. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J Surg Oncol. 2012;10:174. doi:10.1186/1477-7819-10-174.   DOI
18 Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137:1005-1017. doi:10.1016/j.cell.2009.04.021.   DOI
19 Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008;111:3183-3189. doi:10.1182/blood-2007-07-098749.   DOI
20 Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007;67:6130-6135. doi:10.1158/0008-5472.CAN-07-0533.   DOI
21 Farazi TA, Spitzer JI, Morozov P, Tuschi T. miRNAs in human cancer. J Pathol. 2011;223:102-115. doi:10.1002/path.2806.   DOI
22 Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67:8699-8707. doi:10.1158/0008-5472.CAN-07-1936.   DOI
23 Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006;5:24. doi: 10.1186/1476-4598-5-24.   DOI
24 Kyle RA, Therneau TM, Rajkumar SV. Prevalence of monoclonalgammopathy of undetermined significance. N Engl J Med. 2006;354:1362-1369. doi: 10.1056/NEJMoa054494.   DOI
25 Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol. 2009;219:214-221. doi:10.1002/path.2586.   DOI
26 Choi WS, Kwon KC. Expression of microRNA in paraffin embedded tissue of multiple myeloma. Korean J Clin Lab Sci. 2015;47:292-297. doi:https://doi.org/10.15324/kjcls.2015.47.4.292.   DOI
27 Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD, Wang CW, et al. Expression profile of microRNAs in young stroke patients. PLoS One. 2009;4:e7689. doi:10.1371/journal.pone.0007689.   DOI
28 Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:538-548. doi:10.1016/S1470-2045(14)70442-5.   DOI
29 Wu W. MicroRNA: potential targets for the tevelopment of novel drugs?. Drugs R D. 2010;10:1-8. doi:10.2165/11537800-000000000-00000.   DOI
30 Di Martino MT, Gulla A, Gallo Cantafio ME, Altomare E, Amodio N, Leone E, et al. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. PLoS One. 2014;9:e89659. doi:10.1371/journal.pone.0089659.   DOI
31 Went P, Mayer S, Oberholzer, Dirnhofer S. Plasma cell quantification in bone marrow by computer-assisted image analysis. Histol Histopathol. 2006;21:951-956. doi: 10.14670/HH-21.951.
32 Xiang T, Hu AX, Sun P, Liu G, Liu G, Xiao Y. Identification of four potential predicting miRNA biomarkers for multiple myeloma from published datasets. Peer J. 2017;31:e2831. doi:10.7717/peerj.2831.